176 related articles for article (PubMed ID: 16258420)
41. [Treatment of chronic myeloid leukemia with imatinib. A case of translational medicine].
Dosne Pasqualini C
Medicina (B Aires); 2010; 70(3):293-6. PubMed ID: 20529782
[No Abstract] [Full Text] [Related]
42. [Treatment of chronic myelogenous leukemia with imatinib: current and future therapeutic strategies].
Yagasaki F
Nihon Rinsho; 2007 Jan; 65 Suppl 1():505-10. PubMed ID: 17474456
[No Abstract] [Full Text] [Related]
43. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Moser AM; Manor E; Narkis G; Kapelushnik J
Cancer Genet Cytogenet; 2006 Oct; 170(1):54-7. PubMed ID: 16965955
[TBL] [Abstract][Full Text] [Related]
44. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
Arancibia AM; Bendit I; Epelman S
Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
[No Abstract] [Full Text] [Related]
45. Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia.
Jin J; Chen H; Cao L
Leuk Res; 2009 Jun; 33(6):e18-9. PubMed ID: 19108890
[No Abstract] [Full Text] [Related]
46. Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
Ditschkowski M; Haferlach C; Schulte C; Trenschel R; Beelen DW
Bone Marrow Transplant; 2009 Aug; 44(4):265-6. PubMed ID: 19234516
[No Abstract] [Full Text] [Related]
47. Clinical results with imatinib in chronic myeloid leukaemia.
Crossman LC; O'Brien S
Leuk Res; 2004 May; 28 Suppl 1():S3-9. PubMed ID: 15036936
[TBL] [Abstract][Full Text] [Related]
48. Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
Dvorak P; Hruba M; Subrt I
Leuk Res; 2009 Jun; 33(6):860-1. PubMed ID: 18977531
[No Abstract] [Full Text] [Related]
49. [Molecular monitoring: an essential component of the treatment for chronic myeloid leukemia].
Lange T; Pelz-Ackermann O; Burkhardt R; Niederwieser D
Dtsch Med Wochenschr; 2006 Oct; 131(43):2390-4. PubMed ID: 17054054
[No Abstract] [Full Text] [Related]
50. Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.
Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Messina A; Di Raimondo F
Leuk Res; 2009 Jun; 33(6):e17. PubMed ID: 19036439
[No Abstract] [Full Text] [Related]
51. Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 synthase expression and activity in chronic myeloid leukaemia.
Roos C; Stenke L; Ohm L; Widell S; Kumlin M; Lindgren JA; Tornhamre S
Br J Haematol; 2008 Sep; 142(6):992-5. PubMed ID: 18573108
[No Abstract] [Full Text] [Related]
52. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
53. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Radojkovic M; Ristic S; Pavlovic S; Colovic M
Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
[TBL] [Abstract][Full Text] [Related]
54. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M
Bone Marrow Transplant; 2007 Feb; 39(3):189-91. PubMed ID: 17211436
[No Abstract] [Full Text] [Related]
55. Update on the use of imatinib mesylate.
Sawyers CL
Clin Adv Hematol Oncol; 2005 Oct; 3(10):757-8. PubMed ID: 16258483
[No Abstract] [Full Text] [Related]
56. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Kantarjian H; O'Brien S; Talpaz M; Borthakur G; Ravandi F; Faderl S; Verstovsek S; Rios MB; Shan J; Giles F; Cortes J
Cancer; 2007 Apr; 109(8):1556-60. PubMed ID: 17342766
[TBL] [Abstract][Full Text] [Related]
57. Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim DW; Chung YJ; Lee S; Kim YJ; Chung NG; Kim JA; Oh IH; Kim TG; Kim YL; Goh HG; Kim SH; Cho B; Kim HJ; Min CK; Lee JW; Jin JY; Han CW; Kim JW; Min WS; Kim HK; Kim CC; Kim HJ
Leukemia; 2004 Nov; 18(11):1907-9. PubMed ID: 15356641
[No Abstract] [Full Text] [Related]
58. Optimizing therapy of chronic myeloid leukemia.
Deininger MW
Exp Hematol; 2007 Apr; 35(4 Suppl 1):144-54. PubMed ID: 17379100
[TBL] [Abstract][Full Text] [Related]
59. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
[TBL] [Abstract][Full Text] [Related]
60. Questioning the aim of CML therapy in the era of Imatinib?
Carella AM
Leukemia; 2003 Jun; 17(6):1199-200. PubMed ID: 12764394
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
